Announcements /
René Salazar Speaker Series: "E62 bio: Providing Life-Science Solutions for Neglected Diseases and Underserved Communities" on 6/11
Please join LatinX@Broad in promoting and highlighting diversity in academic disciplines within and outside the Broad. Register for our next talk, to be held Tuesday, June 11th, 2024.
Image
René Salazar Speaker Series

All are welcome to join us for our next scheduled René Salazar Speaker Series talk held by LatinX@Broad:

"E62 bio: Providing Life-Science Solutions for Neglected Diseases and Underserved Communities"

Tuesday, June 11th, 2024
2:00-3:00 pm
Zoom 


Registration is required via Zoom, to register please visit: http://broad.io/LatinX_Talks 

Dr. Lucas Marinho

Associate Research Scientist
Heart Institute of University of São Paulo
São Paulo Brazil

Abstract

E62Bio is an early-stage biotech company focused on providing life-science solutions for neglected diseases and populations, particularly in the developing world. The unaddressed and under financed burden of neglected diseases affects approximately 2.7 billion people worldwide, resulting in economic losses of USD 21 billion annually. Our team comprises MIT and Harvard-trained MDs, financiers, and economists from both the United States and developing countries. We have significant experience in medicine, scientific research, public health, and investment banking, and we are supported by a network of best-in-class technical advisors. Our approach applies portfolio theory to biotechnology, allowing us to simultaneously invest in multiple technologies to mitigate the risks associated with pre-clinical, Phase I, and Phase II trials.


Speaker Bio

Dr. Lucas Marinho is a dedicated and compassionate cardiologist specializing in the investigation and treatment of cardiovascular diseases. With a strong background in inflammatory mechanisms in cardiovascular disease, Dr. Marinho has been at the forefront of pioneering innovative treatments for atherosclerosis. During his PhD, he led research on the clinical application of new treatments for atherosclerosis, utilizing anti-inflammatory and antiproliferative drugs associated with nanoparticles in a groundbreaking clinical study.
Since 2021, Dr. Marinho has been a Lemman fellow at Brigham and Women's Hospital, where he has been involved in a significant project employing epidemiological methods to assess the role of inflammation and calcification in peripheral artery disease (PAD) and new treatments for patients with diabetic foot ulcers. He was notably awarded the Robert W. Hobson II MD Early Career Investigator Award from the AHA Council of Peripheral Vascular Disease in 2022.


Dr. Marinho also plays a crucial role as an investigator and member of the adjudicating committee in multicenter cardiovascular trials, with results being presented at major cardiovascular conferences.
In addition, he has been deeply involved in healthcare innovation. He is currently a member of MIT Hacking Medicine and leads MIT Hacking Medicine initiatives in Brazil. In 2023, he co-founded E62Bio with other MBA/MPH Harvard/MIT students. E62Bio is an early-stage biotech company focused on providing life-science solutions for neglected diseases and populations, particularly in the developing world.

Questions? Email latinx-sc@broadinstitute.org.

 

 

René Salazar Speaker Series